Skip to main content

Lettmann Jason's Form 4 filing

Alx Oncology Holdings Inc (ALXO) · filed Dec 10, 2021

Accession no.
0001209191-21-069154
Filed
Dec 10, 2021
Trade date
Dec 8-10, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 16 non-derivative transactions. Open-market sales total $4.70M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lettmann JasonCIK 0001688269Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 8, 2021Common StockSSaleDisposed−35,836$33.23F1−$1,190,830.282,232,251Indirect
Dec 8, 2021Common StockSSaleDisposed−4,883$33.23F1−$162,262.09304,339Indirect
Dec 8, 2021Common StockSSaleDisposed−1,531$33.80F4−$51,747.82,230,720Indirect
Dec 8, 2021Common StockSSaleDisposed−208$33.80F4−$7,030.4304,131Indirect
Dec 9, 2021Common StockSSaleDisposed−11,452$31.08F5−$355,928.162,219,268Indirect
Dec 9, 2021Common StockSSaleDisposed−1,560$31.08F5−$48,484.8302,571Indirect
Dec 9, 2021Common StockSSaleDisposed−42,203$32.06F6−$1,353,028.182,177,065Indirect
Dec 9, 2021Common StockSSaleDisposed−5,751$32.06F6−$184,377.06296,820Indirect
Dec 9, 2021Common StockSSaleDisposed−14,028$32.73F7−$459,136.442,163,037Indirect
Dec 9, 2021Common StockSSaleDisposed−1,911$32.73F7−$62,547.03294,909Indirect
Dec 10, 2021Common StockSSaleDisposed−7,093$30.77F8−$218,251.612,155,944Indirect
Dec 10, 2021Common StockSSaleDisposed−967$30.77F8−$29,754.59293,942Indirect
Dec 10, 2021Common StockSSaleDisposed−15,942$31.55F9−$502,970.12,140,002Indirect
Dec 10, 2021Common StockSSaleDisposed−2,172$31.55F9−$68,526.6291,770Indirect
Dec 10, 2021Common StockSSaleDisposed−88$32.16−$2,830.082,139,914Indirect
Dec 10, 2021Common StockSSaleDisposed−12$32.16−$385.92291,758Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.70 to $33.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.70 to $33.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $31.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.12 to $31.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.15 to $32.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)